linjc16/ctgov huggingface dataset:
Monitoring of Glycocalyx for Prediction of Complications After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational study of the evolution of the microcirculation and the sublingual glycocalyx in perioperative cardiac surgery under cardiopulmonary bypass. Our main objective is to evaluate the prognostic value of the variation of the thickness of the perioperative glycocalyx for the occurrence of a major complication in the first 24 hours after surgery.

Official Title
-----------------
Evaluation de l'utilité du Monitorage du Glycacalyx Pour prédire Les Complications du Patient de Chirurgie Cardiaque

Conditions
-----------------
Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Patient of legal age (age ≥ 18 years) Patient undergoing scheduled cardiac surgery with cardiopulmoary bypass (CPB) (expected duration of CPB > 60 min) Person informed with collection of non-opposition at the latest, the day before the operation - Person affiliated to a social security system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycocalyx thickness variation | Change in glycocalyx thickness between the preoperative period and the postoperative period (2 hours after the end of cardiopulmonary bypass). | Two hours after the end of cardiopulmonarybypass | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycocalyx, Microcirculation, Cardiopulmonary bypass, Organ failure
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease

Study Overview
=================
Brief Summary
-----------------
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.

Detailed Description
-----------------
Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.

Official Title
-----------------
Clinical Understanding Through Real-world Data to Validate Effectiveness of Treatments in Peyronie's Disease

Conditions
-----------------
Peyronie's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Any adult with a confirmed clinical diagnosis of PD. Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment. Willing to participate in the registry (including completion of ePROs) and complete the informed consent form. Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment. Able to participate in English based registry. Key Exclusion criteria: Not having a clinical diagnosis of PD. Age less than 18 years. Do not provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Receiving Each Treatment Type for PD |  | Up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score |  | Up to 12 months | 
| Change from Baseline in International Index of Erectile Function (IIEF) Score |  | Up to 12 months | 
| Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score |  | Up to 12 months | 
| Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score |  | Up to 12 months | 
| Participant Satisfaction Questionnaire |  | Up to 12 months | 
| Number of Participants Receiving Post-Procedural Care by the Treating Physician |  | Up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Real world data, Retrospective, Prospective, Registry
Natural Course of Homocysteine After Uneventful Total Joint Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to asses the natural course of blood homocysteine levels in patients who underwent primary total joint arthroplasty surgery. The main question[s] it aims to answer are: İs homocysteine a good marker for determining periprosthetic joint infection ? İs homocysteine more sensitive marker for periprosthetic joint infections ?

Official Title
-----------------
Natural Course of Homocysteine After Uneventful Total Joint Arthroplasty

Conditions
-----------------
Joint Prosthesis; Complications, Infection or Inflammation

Intervention / Treatment
-----------------
* Diagnostic Test: Blood works for homocysteine levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People who have undergone Total Knee Arthroplasty operation People who have undergone Total Hip Arthroplasty operation Exclusion Criteria: People who have undergone total knee arthroplasty operation and developed a periprosthetic joint infection People who have undergone total hip arthroplasty operation and developed a periprosthetic joint infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arthroplasty Patients<br>Only one group that consist patients who underwent primary total joint arthroplasty | Diagnostic Test: Blood works for homocysteine levels<br>* In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Homocysteine | Homocysteine levels in patient blood works | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
periprosthetic joint infection, diagnosis, natural course, total joint arthroplasty.
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants. Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice

Official Title
-----------------
A Prospective, Multi-center, Post-marketing, Observational Study to Evaluate the Safety and Effectiveness of Upadacitinib in Chinese Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Conditions
-----------------
Atopic Dermatitis (AD)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment. Chinese adolescents (≥12 to <18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment. Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label. The decision to prescribe Upadacitinib is made prior to and independently of study participation. Exclusion Criteria: Participants who cannot be treated with Upadacitinib as per China label or by judgement of treating physician. Currently participating in any interventional research studies.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Upadacitinib<br>Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With Incidence of Serious Infections | Incidence rate of serious infections in AD participants treated with Upadacitinib will be assessed. | Up to approximately 25 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RINVOQ, Atopic Dermatitis (AD), Upadacitinib
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases

Study Overview
=================
Brief Summary
-----------------
Relying on fever clinics, this project evaluates the clinical diagnostic efficiency of the three-level pathogen diagnostic system, monitors changes in respiratory pathogens, and realizes real-time monitoring and early warning of acute respiratory infectious diseases in Shanghai.

Detailed Description
-----------------
This study mainly includes subjects who enter the outpatient and emergency departments, fever clinics, and wards of each center from December 2022. According to the clinical manifestations and epidemiological information of the patients, different step-by-step detection methods will be adopted to optimize the allocation of clinical resources and improve the quality of life. This study aims to improve pathogen diagnosis efficiency and achieve regional respiratory early warning.

Official Title
-----------------
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases

Conditions
-----------------
Respiratory Infectious Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute onset within one week; 18-70 years old; Present with pneumonia (present with pulmonary signs or radiological changes) or influenza-like illness (including the following symptoms: sudden onset of fever (>38 ℃),plus cough and/or other respiratory symptoms such as shortness of breath plus one or more systemic symptoms (fatigue, headache ect.)) Exclusion Criteria: Unable to collect nasal/nasopharyngeal swab/wash/aspirate due to structural disorder or mental problem. Patients with psycological problem or unconsciousness who cannot tell the disease history and cooperate with medical examinations;

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the detectioin rate of pathogenic microorganism in each step | the detectioin rate of pathogenic microorganism in each step | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospitalization rate | hospitalization rate | 48 hours | 
| rate of critical illness | rate of critical illness | 48 hours |
Augmented Reality Game-based Training on Social Communication of Children With Autism Spectrum Disorder

Study Overview
=================
Brief Summary
-----------------
The study aims to determine the effects augmented reality game-based training on social communication of children with autism spectrum disorder.

Detailed Description
-----------------
Augmented Reality allows children to see a representation of imaginary content and pretend play overlaid on the real-world environment. Today, technology can be a safe and motivating way of engaging children with autism in social interaction activities. Current research in therapeutic technology for autism is aimed toward improving behavior and psychomotor activities that impact social communication. The aim of this research project is to help teachers, parents, practitioners, and researchers to understand the unique strengths of their children with autism along with technology based educational and therapeutic activities for home and classroom.

Official Title
-----------------
Effects of Augmented Reality Game-based Training on Social Communication of Children With Autism Spectrum Disorder

Conditions
-----------------
Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Other: Augmented Reality based games
* Other: Traditional therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants diagnosed with autism spectrum disorder in the age range of 5-12 years at verbal imitation and 1-step command following. Exclusion Criteria: Sensory issues and patients on medication.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AR group<br>Augmented Reality based games | Other: Augmented Reality based games<br>* Games of Wonder Tree Augmented Reality<br>|
| Active Comparator: Traditional therapy group<br>Traditional therapy | Other: Traditional therapy<br>* Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Social Responsiveness Scale | The Social Responsiveness Scale, Second Edition (SRS-2) measures social ability of children to adults. It is used primarily with individuals on the autism spectrum, family members of individuals on the autism spectrum, and others who have social impairments. | After 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autism, Augmented Reality, Social communication
Assessment of Right Ventricular Function in Patients With Severe Mitral Stenosis Before and After Balloon Mitral Valvuloplasty

Study Overview
=================
Brief Summary
-----------------
To detect short-term impacts of successful balloon mitral valvuloplasty on right ventricular function

Detailed Description
-----------------
In patients with mitral valve stenosis, right ventricular failure may develop either by the rheumatic process directly or through hemodynamic alterations resulting from pulmonary vascular changes. Right ventricular (RV) function plays an important role in development of clinical symptoms and prognosis in patients with mitral stenosis (MS).This is primarily affected by hemodynamic effects on RV due to pulmonary hypertension(PH). In the last two decades, Percutaneous Transluminal Mitral Commissurotomy (PTMC) has become the treatment of choice for patients with symptomatic rheumatic MS . Using this method,Mitral Valve Area (MVA) can be increased, which can improve the hemodynamic and clinical features of patients with MS . RV functional assessment is difficult and not done routinely because of its complex anatomy and high load dependence. Different modalitis are used to assess RV function as Tissue Doppler and two-dimensional (2D) speckle tracking method has been used to quantify strain for assessment Myocardial strain is a measure of tissue deformation, which is expressed as a percentage change.

Official Title
-----------------
Assessment of Right Ventricular Function in Patient With Severe Mitral Stenosis Before and After Balloon Mitral Valvuloplasty

Conditions
-----------------
Mitral Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with isolated mitral stenosis (except those with mild mitral regurgitation and are candidate for PTMC by 2D Echo evaluation). Patient with normal left ventricular EF. patient with sinus rhythm or AF patient with any degree of pulmonary HTN Exclusion Criteria: Patient with another valve lesion or more than mild mitral regurgitation. Patient with impaired cardiac function. patient with coronary arteries disease Mitral stenosis of other etiology than rheumatic origin.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare RV function before and after PTMC | echocardiogram | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure the right side pressure changes invasively before and after PTMC | Right sided heart catheterization | 1 year | 
| To compare the effect of PTMC on RV function in patient with AF and sinus rythm |  | 1year |
High- Versus Low-calcium Water for Bone Health

Study Overview
=================
Brief Summary
-----------------
The experimental study investigates which metabolic responses of calcium and parathyroid hormone are observable in blood and urine in a cohort of 41 healthy adults following a sequence of different exposures: low-calcium water first and high-calcium water afterward.

Official Title
-----------------
Metabolic Response to the Consumption of Waters With Different Calcium Content: a Cross-over Clinical Study

Conditions
-----------------
Orthopedic Disorder, Calcium Metabolism Disorders, Bone Resorption, Water-Electrolyte Imbalance, Eating, Healthy

Intervention / Treatment
-----------------
* Other: Loading of low-calcium water first, then high-calcium water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index ≥ 18 and < 30 Maintenance of diet and physical activity lifestyle throughout the duration of the study Acceptance of informed consent Exclusion Criteria: Consumption of water with calcium > 150 mg/L Pregnancy (as established by self-declaration), breastfeeding, menopause Inability to follow the study protocol Cardiac, vascular, renal, and oncological disease Neuropsychiatric disease, developmental disorders Disease or past surgery affecting the gastrointestinal tract Drugs that interfere with bone (e.g. corticosteroids) or with fluid balance (e.g. diuretics)

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low-calcium water first, then high-calcium water<br>Participants drink 1.5 L of the designated water | Other: Loading of low-calcium water first, then high-calcium water<br>* All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of blood calcium levels | Change of calcium levels (mg/dL) from baseline and after 2.5 hours | Baseline and 2.5 hours |